Overview
Novartis is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals medicines. In late 2023, the company reorganized its operations into five organizational units. These are Biomedical Research, Development, Operations, and two commercial units: US and International. Global functions support these organizational units in the execution of their work. We
...
Read More are engaged in the research, development, manufacturing, distribution, and commercialization and sale of innovative medicines, with a focus on the core therapeutic areas: cardiovascular, renal and metabolic; immunology; neuroscience; and oncology; as well as established brands. Novartis sells its products in about 130 countries and generates most of its revenue from international customers. In 2023, Novartis completed its transformation into a pure-play innovative medicines business, with the successful spin-off of Sandoz.
Read Less
Read More are engaged in the research, development, manufacturing, distribution, and commercialization and sale of innovative medicines, with a focus on the core therapeutic areas: cardiovascular, renal and metabolic; immunology; neuroscience; and oncology; as well as established brands. Novartis sells its products in about 130 countries and generates most of its revenue from international customers. In 2023, Novartis completed its transformation into a pure-play innovative medicines business, with the successful spin-off of Sandoz.
Read Less
Vasant Kalathur Narasimhan
See more contacts
Management of Companies and Enterprises
,
Holding companies, nec
?
?
Actual
$57.13 billion
Actual
10.85%
-19.59%
$102,246
DEC
?
?
Swiss:NOVN
Contacts
Get in Touch with 28 Principals*
-
Vasant Kalathur NarasimhanManaging Director and Chairperson
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$57.13 billion
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $17,619 | $14,458 | $14,236 |
| Net Investing Cash | -$7,513 | $5,596 | $1,468 |
| Net Financing Cash | -$11,742 | -$14,278 | -$20,562 |
| Net Change in Cash | -$1,636 | $5,776 | -$4,858 |
| Cash at Beginning of Period | $13,393 | $7,517 | $12,407 |
| Cash at End of Period | $11,459 | $13,393 | $7,517 |
| Capital Expenditure | -$3,814 | -$2,753 | -$2,239 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $11,459 | $13,393 | $7,517 |
| Accounts Receivable | $7,423 | $7,107 | $8,066 |
| Inventories | $5,723 | $5,913 | $7,175 |
| Other Current Assets | $5,099 | $4,068 | $14,152 |
| Asset Summary | |||
| Total Current Assets | $29,704 | $30,481 | $36,910 |
| Tangible Fixed Assets | $10,873 | $10,924 | $12,195 |
| Intangible Assets | $26,915 | $26,879 | $31,644 |
| Total Assets | $102,246 | $99,945 | $117,453 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $4,572 | $4,926 | $5,146 |
| Short-Term Debt | $8,089 | $6,084 | $5,876 |
| Other Current Liabilities | $16,031 | $15,380 | $17,634 |
| Liability Summary | |||
| Total Current Liabilities | $28,692 | $26,390 | $28,656 |
| Long-Term Debt | $21,366 | $18,436 | $20,244 |
| Other Long-Term Liabilities | $1,041 | $1,193 | $1,578 |
| Total Liabilities | $58,120 | $53,195 | $58,030 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $793 | $825 | $890 |
| Retained Earnings | $46,561 | $49,649 | $63,540 |
| Equity Summary | |||
| Total Equity | $44,046 | $46,667 | $59,342 |
| Shares Outstanding | 1,975,089,248 | 2,044,033,986 | 2,119,609,057 |